RecruitMe Clinical Trial

Protocol ARC003: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (The Palisade Study)
A study for children and adults with peanut allergies using study drug AR101
Sponsor:Aimmune Therapeutics, Inc.
Enrolling:Male and Female Patients
Age Range:Between 4 and 55 years old
IRB Number:AAAQ5204
U.S. Government ID:NCT02635776
Contact: Elizabeth Duverger: 929-280-5799 / ed2714@cumc.columbia.edu
Additional Study Information:

This is an experimental research study for individuals with allergy to peanuts or peanut-containing food. Oral (by mouth, not injection) immunotherapy may reduce a patients sensitivity to a specific allergen by exposing the patient to small amounts of the substance causing the allergic reaction and then gradually increasing the amount of allergen over time. Although immunotherapy does not cure an allergy, for many, it lessens the bodys sensitivity to the allergen, resulting in fewer symptoms.

This study is closed
Investigator
Joyce Yu, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Elizabeth Duverger
Email: ed2714@cumc.columbia.edu
Phone: 929-280-5799